Transaction Comparables: How M&A Bankers Use Precedent Deals to Value Targets
Transaction comparables (often shortened to transaction comps, deal comps, or M&A comps) are the set of completed or announced acquisitions an investment banker assembles to triangulate the price a strategic or financial buyer would pay for a target company today. Unlike trading comparables, which read the public equity market’s daily quote on a peer’s enterprise value, transaction comparables capture the all-in negotiated purchase price (including control premium, synergy share, and any earnout) in arm’s-length M&A deals that have actually cleared. Every fairness opinion filed under SEC Item 1015, every sell-side pitch from Goldman Sachs, Houlihan Lokey, Lincoln International, Lazard, or Morgan Stanley, and every Delaware appraisal brief in In re Appraisal of Dell (Del. Ch. 2016) and DFC Global v. Muirfield Value Partners (Del. 2017) leans on transaction comparables as one of three or four anchor methodologies in the valuation football field.
This guide is the working 2026 methodology: where the data comes from, how a banker scrubs and calendarizes the deal set, which multiples actually move negotiation, where the trap doors are (stale dates, undisclosed earnouts, accounting noise), and how transaction comparables interact with discounted cash flow and trading comparables when you build the final valuation range. The mechanics are not academic. Get the comp set wrong and the SEC, the target board, or a Delaware judge will tell you so on the record.
Quick-Reference: Transaction Comparables in 90 Seconds
| Item | Detail |
|---|---|
| Also known as | Transaction comps, deal comps, M&A comps, precedent transactions, acquisition comparables |
| What it values | Enterprise value and equity value at a change-of-control purchase price (including premium and synergy share) |
| Time window typical | Trailing 3 to 5 years of closed deals, sometimes 7 in thin sectors |
| Sample size target | 8 to 15 transactions for a defensible median, 5 minimum for a footnoted range |
| Core multiples | EV / LTM EBITDA, EV / NTM EBITDA, EV / LTM Revenue, EV / EBIT, occasionally EV / (EBITDA – Capex) |
| Primary data sources | SEC EDGAR filings (proxy, 8-K, S-4, tender offer 14D-9), Pitchbook, S&P Capital IQ, Refinitiv Deals Intelligence, MergerMarket, Bloomberg M&A |
| Cost of data | S&P Capital IQ ~$13,000/seat/yr, Pitchbook ~$22,000/seat/yr, Bloomberg Terminal $32,025/yr per Bloomberg’s own price card |
| Time to build (first pass) | 6 to 12 hours with paid databases, 20 to 40 hours from SEC EDGAR alone |
| Where it sits in the football field | Usually rightmost of the three anchor methods, above trading comps, alongside or above standalone DCF |
| Refresh cadence on live deal | Weekly during marketing, immediately when a new in-sector deal is announced |
| Control premium implied | Typically 20 to 40 percent over the target’s unaffected stock price per Mergerstat / FactSet data, sector dependent |
What Transaction Comparables Actually Measure (and Why They Differ From Trading Comps)
A transaction comparable answers a sharper question than a trading comp. Trading comps tell you how the public market prices one share of a peer’s equity on a Tuesday morning. Transaction comparables tell you what an actual buyer paid for 100 percent of the equity, in cash or stock, with full operational control, after a negotiation that included due diligence, exclusivity, financing contingencies, and antitrust review under the Hart-Scott-Rodino Act. The two numbers diverge for a structural reason: the change-of-control price includes a control premium plus the buyer’s share of expected synergies, while a public stock price reflects neither.
Mergerstat (now part of FactSet) has published the standing benchmark for U.S. control premia for decades. For 2024 U.S. public-target transactions, the median 1-day control premium was 32.4 percent over the unaffected price, with the 25th percentile at 20.1 percent and the 75th at 47.8 percent per the FactSet Mergerstat Review 2025. That spread is the empirical reason transaction comparables almost always print at higher multiples than trading comparables on the same target on the same day. Trading multiples reflect a continuous market quote, while transaction multiples are point-in-time observations sampled irregularly when deals close, which makes recency, sector specificity, and deal-size bucketing far more important. A single 2021 mega-deal at 16x EBITDA can pull a small-cap chemicals comp set median three turns higher than the underlying sector reality in 2026; the Wall Street Oasis comps explainer and Mergers and Inquisitions precedent transactions walkthrough document the same distinction the banker curriculum has taught for two decades.
Where the Data Actually Comes From: SEC EDGAR, Capital IQ, Pitchbook, Refinitiv
Every defensible transaction comp set in 2026 starts with one of four primary databases, ranked here by how often a U.S. banker will reach for them on a live mandate.
SEC EDGAR is free, exhaustive, and the only fully auditable source for U.S. public-target deal terms. The relevant filings are the 8-K (exhibit 2.1 contains the merger agreement), the DEFM14A proxy (target’s recommendation and the “Background of the Merger” narrative, with the fairness opinion and projections), the S-4 (stock consideration), and the SC 14D-9 (tender offer recommendation). Cornell’s 17 CFR 229.1015 sets the disclosure standard for fairness opinion exhibits.
S&P Capital IQ (~$13,000/seat/yr) and FactSet (~$12,000/seat/yr) are the workhorses for screening and spreading; the Transactions screen filters by NAICS, geography, deal size, transaction type, payment type, and date range. Refinitiv Deals Intelligence (now LSEG, formerly Thomson Reuters SDC Platinum) is the historical standard for league tables that Lazard, Goldman, and Morgan Stanley quote in pitch covers. Pitchbook (~$22,000/seat/yr) is the most-cited source for private-target deals; it discloses multiples for roughly 30 percent of tracked transactions per the Q4 2025 US PE Breakdown, leaving a selection-bias footnote on the disclosed sample. MergerMarket and Bloomberg M&A cover cross-border and live deal-flow respectively.
One non-obvious source: the acquirer’s first 10-K after closing contains the purchase price allocation under ASC 805 Business Combinations, disclosing fair value of consideration transferred, assets and liabilities acquired, and goodwill recognized. This is the most reliable post-close source for the actual transaction value if announcement-day terms were vague.
Building the Universe: Sector Screens, Date Windows, and Deal-Size Bands
The first step is a sector screen. NAICS 6-digit and SIC 4-digit codes both miss the mark for differentiated businesses; a specialty chemicals set built on NAICS 325 sweeps in commodity petrochemicals, fertilizers, paints, and pharmaceuticals. Start with the broad code from the U.S. Census NAICS directory, then layer a qualitative screen by reading each target’s 10-K business description for end-market overlap, customer concentration, and growth profile.
Date windows: 3 to 5 years standard, with sector-volatility adjustments. Software multiples compressed roughly 40 percent from 2021 peak to 2024 trough per the Software Equity Group 2024 Annual Report, so 2023 to 2024 deals weight heavier than 2021 (or 2021 gets footnoted as “frothy period”). Cyclical sectors (industrials, oil and gas, homebuilders) stretch to 5 to 7 years; thin sectors (specialty aerospace, rare earth refining) may need 10. Deal-size bucketing matters too. Per the Capstone Partners Middle Market M&A Quarterly, deals under $50M EV clear at 4 to 6x EBITDA, $50M to $250M at 6 to 9x, $250M to $1B at 8 to 12x, and above $1B at 10 to 16x depending on sector. Cross-border deals carry a 5 to 10 percent premium over domestic per the JPMorgan 2024 M&A Outlook.
Screening the Universe Into a Defensible Comp Set
A raw Capital IQ pull on a 5-year, sector-filtered query can return 200 to 800 deals. The screening pass that takes the set down to 8 to 15 defensible comps is the most judgment-intensive step in the build. Standard exclusions, all of which should be footnoted in the appendix:
- Undisclosed deal value: If neither the announcement nor the post-close acquirer 10-K discloses purchase price, the deal cannot be used for multiple calculation. Roughly 50 to 70 percent of small private-target deals fall into this bucket.
- Distressed and bankruptcy auctions: 363 sale processes (under Bankruptcy Code Section 363) typically clear at 30 to 60 percent of fair-market enterprise value because of compressed timelines and the absence of representations and warranties. Cornell’s 11 U.S.C. Section 363 codifies the asset-sale framework. Include these only as a separate footnoted set.
- Minority stake purchases: Any deal acquiring less than 50.1 percent of equity is not a control transaction and should not be in the main set.
- Intercompany restructurings: Parent-to-subsidiary or sister-company transfers do not reflect arm’s-length pricing.
- Mega-deals as outliers: If a single deal is more than 5x the size of the median in the set, it warrants separate treatment because synergy economics and antitrust dynamics differ at mega-cap scale.
- Stale deals: Deals announced before the most recent macro regime change (for 2026 builds, this often means pre-March-2022 deals announced before the Fed funds rate started moving above 1 percent).
Once the exclusions run, the typical 800-deal raw pull becomes a 40 to 60 deal “long list” and then a 10 to 15 deal “short list” after the qualitative business-fit screen. Document every exclusion in a screening log; opposing counsel in Delaware appraisal litigation will ask why each excluded deal was excluded.
Calculating Enterprise Value at the Transaction Date: The Five-Line Bridge
The single most common mistake in junior-banker transaction comp models is wrong enterprise value math. The deal value reported in the announcement press release is rarely the enterprise value, and the proxy fairness opinion footnote is the only authoritative source. The professional five-line bridge:
| Line | Item | Source |
|---|---|---|
| 1 | Equity purchase price (offer price per share x fully diluted shares) | Merger agreement, exhibit 2.1 of 8-K |
| 2 | Plus: net debt assumed (total debt minus cash and marketable securities) | Target’s last 10-Q before signing |
| 3 | Plus: preferred stock at liquidation value | Target’s last 10-K capital structure note |
| 4 | Plus: noncontrolling interest at book or fair value | Target’s last 10-K |
| 5 | Plus or minus: pension underfunded liability or overfunded asset (after tax) | Target’s last 10-K pension footnote |
| = | Transaction enterprise value |
Fully diluted shares is itself a sub-calculation. The treasury stock method under ASC 260 Earnings Per Share is the standard: in-the-money options add to the count net of strike-price repurchases; RSUs and PSUs add at 100 percent if the deal triggers vesting (most single-trigger plans do, per the annual Skadden Insights compensation review showing 85 percent S&P 500 prevalence). Earnouts are the other trap: include the fair value of contingent consideration as reported in the acquirer’s post-close 10-K under ASC 805; pre-close, use the midpoint of the disclosed range and discount at 10 to 15 percent per the AICPA business-combinations guide.
Picking the Right Multiples for the Sector and the Cycle
The default M&A multiple is EV / LTM EBITDA, but it is not always the right answer. The sector dictates the multiple, and the cycle dictates which period (LTM or NTM) you anchor to.
| Sector | Primary multiple | Secondary multiple | Why |
|---|---|---|---|
| Software / SaaS | EV / NTM Revenue (rule of 40 weighted) | EV / NTM EBITDA | Negative LTM EBITDA common; growth pricing dominates |
| Industrials and manufacturing | EV / LTM EBITDA | EV / (EBITDA – Capex) | Capex intensity differentiates real margin |
| Specialty chemicals | EV / LTM EBITDA | EV / EBITDAR | Cycle-normalized margin matters; lease adjustment for asset-heavy |
| Consumer / retail | EV / LTM EBITDA | EV / LTM Sales | Margin volatility makes EBITDA noisy; revenue stabilizes |
| Financial institutions (banks, insurers) | P / TBV (price to tangible book value) | P / E forward | Enterprise value not meaningful for deposit-funded businesses |
| Real estate | Cap rate (NOI yield) | EV / FFO | Income-property convention; REIT-specific FFO under Nareit FFO White Paper |
| Energy upstream | EV / Proved Reserves ($/boe) | EV / Flowing Barrel | Reserve-based asset valuation per SEC Rule 4-10 |
| Biotech (pre-revenue) | EV / Pipeline NPV | Per indication PoS-adjusted | Probability-adjusted DCF dominates because no current cash flow |
| Asset management | EV / AUM and EV / Management Fees | EV / EBITDA | Fee-paying AUM is the durable economic unit |
LTM versus NTM matters in inflection-point sectors. If the target is growing 30 percent year over year, the LTM multiple prints 30 percent lower than NTM on the same EV, and the buyer paid for NTM. Always footnote the period; the Lincoln International Senior Lender Survey publishes quarterly LTM vs NTM EBITDA multiples by sector for the U.S. private mid-market.
One LTM-vs-NTM subtlety: calendarization. Restating a target’s financials so the LTM period matches the deal-announcement date often requires a stub-add and stub-subtract from the most recent 10-K. Interim periods are not audited and often restated, so the professional convention is to use the figures from the proxy fairness opinion under 17 CFR 229.1015 or, for private targets, the figures in the merger agreement’s representations and warranties (typically Article III). For NTM, use management projections approved by the target’s board, not sell-side analyst consensus; the In re Appraisal of Dell opinion (Del. Ch. 2016, the 152,000-word VC Travis Laster decision available via Delaware Courts) spent dozens of pages rejecting comps because of projection-period mismatches.
Control Premium, Synergy Share, and Buyer Type
The implicit control premium decomposes into three pieces: the standalone value the seller gives up, the buyer’s share of expected synergies, and the seller’s share (which is the premium itself). The Houlihan Lokey 2024 Premium Studies report median acquirer synergy capture at 30 to 40 percent of announced synergies, with 60 to 70 percent passed through to the seller as premium. Strategic buyers and financial buyers price synergies differently.
| Buyer type | Synergy assumption | Typical EBITDA premium vs trading comps | Source / convention |
|---|---|---|---|
| Strategic acquirer (same sector) | 15 to 25 percent of target revenue in cost synergies, 2 to 5 percent revenue synergies | 2 to 5 turns higher | BCG M&A Report 2024 |
| Adjacent strategic (different sector, same customer) | 5 to 12 percent revenue cross-sell, modest cost synergies | 1 to 3 turns higher | McKinsey M&A Practice 2024 |
| Financial buyer / PE platform deal | Operating efficiency and add-on tuck-in synergies only, modeled in LBO IRR | 0 to 1 turn higher than trading | Bain Global PE Report 2025 |
| Financial buyer / add-on to existing platform | SG&A and procurement consolidation, 5 to 15 percent of target SG&A | 1 to 2 turns higher | Lincoln International Mid-Market 2024 |
| Distressed / activist / hostile | Variable; often discount to trading | Negative to 1 turn | Wachtell Lipton Takeover Defense Update |
The professional convention in fairness opinions is to split the transaction comp set by buyer type and present separate medians. The 2024 fairness opinion in the $28 billion Cisco / Splunk deal (filed via DEFM14A on EDGAR) disclosed a strategic-buyer comp set median of 31x EBITDA versus a financial-buyer set median of 21x, framing the negotiated 36x multiple as a strategic-buyer premium for synergy capture. Reuters coverage walked through the bridge.
The Statistics Output: Min, 25th, Median, Mean, 75th, Max
The output of a transaction comp build is a six-statistic distribution on each multiple. Median is the anchor (less sensitive to mega-deal outliers than mean), 25th and 75th percentiles bracket the negotiation range, min and max identify the outliers worth footnoting. The professional format on a banker pitch page:
| Statistic | EV / LTM EBITDA | EV / NTM EBITDA | EV / LTM Revenue |
|---|---|---|---|
| Min | 6.2x | 5.4x | 1.1x |
| 25th percentile | 8.7x | 7.8x | 1.6x |
| Median | 10.5x | 9.4x | 1.9x |
| Mean | 10.9x | 9.8x | 2.1x |
| 75th percentile | 12.3x | 11.1x | 2.4x |
| Max | 15.8x | 14.2x | 3.4x |
The valuation range presented to a board is typically the 25th to 75th percentile, with the midpoint being the median. So in the example above, the implied EV range on $100 million LTM EBITDA would be $870 million to $1.23 billion (median $1.05 billion). Some bankers present 1st quartile to 3rd quartile, others present the interquartile range plus a control-premium adjustment; the disclosure has to be transparent or the fairness opinion is vulnerable on cross-examination.
Reading the Footnotes: Why Multiples Diverge Across Deals
A 10.5x median EBITDA multiple across 12 deals is rarely a tight clustering. The dispersion (8x to 15x for example) is the analytical product, and the footnotes explain it. Five recurring drivers:
- Growth rate differential: A target growing 25 percent year over year prints a multiple 3 to 6 turns higher than a flat target with the same EBITDA dollars. The Gordon growth model implies that EV / NOPAT = 1 / (WACC – g), so a 5 percent decline in WACC or 2 percent rise in g compresses the denominator and expands the multiple by 30 to 50 percent.
- Margin profile: 20 percent EBITDA margins trade 1 to 2 turns above 12 percent margin businesses because higher-margin businesses convert more incremental revenue to free cash flow.
- Strategic versus financial buyer: 2 to 5 turn spread as documented above.
- Cycle position: 2021 software deals at 16x NTM revenue do not inform 2026 software deals at 5x NTM revenue; the macro regime change matters.
- Customer concentration and contract structure: A 50 percent customer concentration discounts the multiple 2 to 4 turns; a recurring subscription contract structure premiums it 1 to 3 turns.
The professional convention is a 200 to 400 word footnote table explaining each comp’s outlier characteristics. The annual Wachtell Lipton M&A Activity Review and the Cooley M&A insights document the cases where weak footnotes became plaintiff exhibits in Delaware deal litigation.
Worked Example: Mid-Market Industrial Distribution Target
Consider a hypothetical target: $185 million LTM revenue, $28 million LTM EBITDA (15.1 percent margin), 8 percent organic revenue growth, $12 million annual capex, $40 million net debt, no preferred or pension liabilities. The target is a regional electrical-products distributor in the Southeast. The transaction comp set assembled from Pitchbook, Capital IQ, and SEC EDGAR over a 2022 to 2025 window:
| Target | Acquirer | Year | EV ($M) | EBITDA ($M) | EV / EBITDA | Notes |
|---|---|---|---|---|---|---|
| Sonepar US (specialty) | Sonepar SA | 2024 | 425 | 38 | 11.2x | Strategic, cross-border, synergy-heavy |
| Border States subsidiary divestiture | WESCO | 2023 | 180 | 22 | 8.2x | Carve-out, lower multiple |
| Friedman Industries Electrical | Rexel | 2024 | 295 | 31 | 9.5x | Strategic, recurring contracts |
| City Electric Supply unit | Graybar | 2025 | 220 | 23 | 9.6x | Strategic, geographic fill-in |
| Independent Electric Supply | Sentinel Capital | 2023 | 155 | 17 | 9.1x | Financial buyer, platform deal |
| Crawford Electric Supply | Sonepar | 2022 | 340 | 32 | 10.6x | Strategic, frothy 2022 cycle |
| USESI add-on | Clayton, Dubilier & Rice | 2024 | 200 | 21 | 9.5x | PE add-on, tuck-in synergies |
| Munch’s Supply | Roper-backed platform | 2025 | 165 | 19 | 8.7x | Mid-market PE, lower mid bound |
Statistics on this 8-deal set: median 9.4x, mean 9.6x, 25th percentile 9.1x, 75th percentile 9.95x. Applied to the target’s $28 million LTM EBITDA: median EV of $263 million, IQR range of $254 million to $279 million. After subtracting $40 million net debt, implied equity value is $214 million to $239 million with a median of $223 million.
The footnote disclosures: the Crawford Electric 10.6x deal was the 2022 cycle peak; weighted down in the analysis. The Sonepar US 11.2x deal had a 25 percent cross-border premium and substantial cost-synergy capture; presented as a separate strategic-buyer ceiling. The Border States carve-out at 8.2x represented a no-rep-warranty divestiture; footnoted as a floor.
The Football Field: Where Transaction Comps Fit Alongside DCF and Trading Comps
A complete valuation presentation places transaction comparables alongside three other methodologies in the football field chart. The standard 2026 banker presentation:
| Methodology | Implied EV range | Anchor source | Bias |
|---|---|---|---|
| 52-week trading range | Lowest of the four | Public market unaffected price | Excludes control premium; not relevant for private targets |
| Trading comparables (CCA) | Second from bottom | Public peer median multiple | Excludes control premium; reflects daily quote |
| Discounted cash flow (DCF) | Mid-range to high | Management projections, WACC | Sensitive to terminal value and discount rate; intrinsic |
| Transaction comparables (precedents) | Typically highest | Closed-deal median multiple | Includes control premium and synergy share |
The negotiated price is rarely the median of all four; it is usually pulled toward the highest (transaction comps) when there is competitive tension and toward the trading-comps range when there is no competitive process. The Lazard Quarterly Sponsor Survey reports that fully marketed sell-side processes in 2024 closed 18 to 25 percent above the unaffected trading comp median; targeted-buyer or one-off processes closed 5 to 12 percent above. That premium spread is the empirical value of running a real competitive process per the Goldman Sachs M&A Insights.
For a deeper walkthrough of how the DCF methodology builds, work through the discounted cash flow business valuation guide and the related DCF valuation for business sale framework. For the full business valuation math stack, the business valuation formula, methods, and math reference is the companion piece. For how transaction comps interact with the buy-side LBO math, the leveraged buyout model from scratch and LBO model step-by-step guide walk through how a PE buyer reverse-engineers their entry multiple from the same transaction comp universe.
When Transaction Comparables Mislead and You Should Underweight Them
Transaction comparables are powerful, but they are not always the right anchor. Six situations where the methodology is structurally weak and a banker should footnote or underweight it:
- Thin sample: Fewer than 5 deals in the comp set means the median is a statistical artifact. Footnote the small sample and lean on DCF.
- Stale sample: If the most recent comparable deal is more than 24 months old in a fast-moving sector (software, biotech, fintech), the multiples no longer reflect the current cost-of-capital environment.
- Regime-change moment: The Fed rate-hike cycle of 2022 to 2023, the AI capital boom of 2024 to 2025, or any major tax-law change (the 2025 Big Beautiful Bill PUB L 119-21 expiring Section 199A) all create regime breaks where pre-event comps mislead.
- No-disclosure problem: If 60 percent of the relevant sector’s deals do not disclose terms, the disclosed sample is selection-biased toward larger and more strategic deals.
- One-off mega-deal dominance: A single $20 billion megadeal in a sector with $500 million typical deal size cannot anchor smaller comps; treat it as a separate observation.
- Distressed market: 2008 to 2009 deals or 2020 COVID deals are not representative of a normal market. Footnote or exclude.
In any of these situations, the DCF gets more weight in the football field and the transaction comp range gets presented as a sanity check rather than as the primary anchor.
Fairness Opinions, SEC Item 1015, and the Litigation Backstop
Every public-target U.S. M&A deal triggers a board fairness opinion under directors’ fiduciary duties (the Smith v. Van Gorkom Delaware decision, 488 A.2d 858 (Del. 1985), established the modern standard), and the opinion is filed with the SEC under 17 CFR 229.1015. The Item 1015 exhibit must disclose the financial analyses, including the transaction comp set, multiples, implied EV range, and the advisor selection and compensation background. The In re Trulia Inc. Stockholder Litigation ruling (129 A.3d 884 (Del. Ch. 2016)) requires substantive (not perfunctory) Item 1015 disclosures.
The advisor (Goldman, Morgan Stanley, Centerview, Evercore, Houlihan Lokey, Lincoln, Lazard) is on the hook to defend the comp set in litigation. The Davis Polk M&A practice memos and Sullivan & Cromwell M&A reviews document that median Delaware appraisal trials now run 12 to 18 months from filing and that the comp set is the most-litigated valuation methodology. Comp sets with under 5 deals, sets where the largest deal is more than 5x the median, and sets excluding obviously relevant deals without footnoted justification are the ones rejected; the DFC Global Corp. v. Muirfield Value Partners opinion (172 A.3d 346 (Del. 2017)) is the leading appellate precedent.
The comp-set work also informs reps and warranties scoping, the material adverse effect definition (often pegged to a percentage of EV), the 280G golden parachute excise tax analysis (keyed off purchase price), and the stock purchase agreement consideration mechanics.
Cross-border, carve-out, and distressed situations add their own adjustments. Cross-border deals require currency normalization (translate to USD at the announcement-date spot rate from the Federal Reserve H.10 release) and IFRS-to-GAAP bridges (lease accounting IFRS 16 vs ASC 842, goodwill impairment annual under ASC 350 vs continuous under IAS 36). Carve-out comps need a “carve-out adjusted EBITDA” that adds back allocated corporate cost (typically 2 to 4 percent of revenue per Deloitte’s 2024 Divestiture Survey) plus footnoted transition services agreements. Distressed deals under 11 U.S.C. Section 363 clear 30 to 60 percent below fair-market EV per the Edgewater Capital Distressed M&A Annual; treat them as a separate set, not as main-set comps.
Tools, Templates, and Common Mistakes
The professional toolkit: S&P Capital IQ Transactions screen with Excel plug-in (fastest path to a 50-deal pull), Pitchbook desktop for private-target coverage, SEC EDGAR full-text search, Macabacus Excel formatting toolkit, FactSet Mergerstat Review for the control premium benchmark dataset, and the Wachtell Lipton M&A Activity Review for litigation-outcome guidance.
Recurring junior-banker mistakes that get caught in QC, per the Forbes M&A Council and WSJ Deals desk coverage of failed processes:
- Mixing pre-IPO and post-IPO multiples without normalization for liquidity discount.
- Pulling deal value from the press-release headline rather than the proxy fairness opinion footnote.
- Treating an announced-but-not-closed deal as definitive; price often moves between signing and closing if a price-adjustment mechanism or MAE clause is invoked.
- Using fiscal-year financials instead of calendar-year-restated, inflating LTM by the period mismatch.
- Counting earnouts at face value rather than fair value, overstating EV.
- Including bankruptcy-court 363 sales in the main set, dragging the median lower.
- Failing to back out non-recurring items (litigation reserves, restructuring charges, gains on sale) from the EBITDA denominator.
For the underlying career roles that build these comp sets, see the M&A advisor overview, the sell-side analyst career guide, and the private equity analyst career guide for the buy-side analog. For the LBO entry-multiple counterpart, the paper LBO example walkthrough shows how a PE analyst reverse-engineers an entry multiple from the same transaction comp set.
How Transaction Comparables Differ from Precedent Transactions, Trading Comps, and the M&A Comps Family
The terminology in this corner of finance is sloppy and the words overlap in practice. The professional taxonomy:
| Term | What it means | Where you see it |
|---|---|---|
| Transaction comparables | The full universe of closed M&A deals used as multiple-based valuation references; usually synonymous with precedent transactions | Banker pitches, fairness opinions, BIWS / Wall Street Prep curriculum |
| Precedent transactions (PTA) | Same methodology, more formal name; this is the term that appears in fairness opinion exhibits | SEC Item 1015 exhibits, Delaware appraisal opinions |
| Deal comps | Informal industry shorthand for the same dataset | Trading desk and PE deal-team conversation |
| M&A comps | Same methodology, term more common in private-market and mid-market context | Pitchbook research, Capstone Partners reports |
| Trading comparables (CCA) | Distinct methodology using daily public-equity multiples of peer companies; does not include control premium | See the parallel methodology in the how to determine the value of a business guide |
| Public comps | Synonym for trading comparables | Casual usage; do not confuse with public-target transaction comps |
| Football field | The composite valuation chart that integrates all the above methodologies plus DCF and 52-week trading range | Page 1 of any banker pitch book |
The most common confusion in junior associate work is between “public comps” (meaning trading comps on listed peers) and “public-target transaction comps” (meaning M&A deals where the target was a public company). The two share the word “public” but refer to entirely different datasets. Always ask which one is meant.
2026 Market Context and Sector-Specific Multiple Levels
The 2026 transaction comp environment is shaped by the 2022 to 2024 rate-hike cycle, the 2025 partial-rate-cut response, and the 2024 to 2025 boom in AI and infrastructure deals. Selected sector medians for the trailing 24 months (Q1 2024 to Q4 2025), drawn from Lincoln International’s Senior Lender Survey, S&P Capital IQ Mid-Market Indicator, and Pitchbook Q4 2025 PE Breakdown:
| Sector | Median EV / LTM EBITDA (2024 to 2025) | 2021 peak comparison | Direction in 2026 |
|---|---|---|---|
| Vertical SaaS | 12.8x | 22x | Stabilizing; AI-native premium of 4 to 7 turns |
| Industrial distribution | 9.4x | 10.2x | Stable to up; consolidation thesis active |
| Specialty chemicals | 8.7x | 9.5x | Down slightly; petrochemical pricing pressure |
| Healthcare services (multi-site) | 11.2x | 14.5x | Down; PE retreat from regulated sectors after CMS rules |
| Aerospace and defense | 13.5x | 13.1x | Up; defense budget tailwind |
| Consumer brand (DTC) | 2.1x revenue | 4.5x revenue | Compressed; Amazon margin headwind |
| Infrastructure / energy transition | 13.8x | 11.0x | Up; capital reallocation into transition assets |
| Insurance distribution (broker, MGA) | 13.2x | 13.0x | Stable; ongoing roll-up consolidation |
| Food and beverage manufacturing | 9.1x | 10.5x | Down; private-label margin pressure |
| Cybersecurity | 14.5x | 18x | Stable; AI-security premium developing |
Two structural 2026 dynamics deserve emphasis. First, the AI-native premium is real and is reshaping software comps: targets with credible AI-product positioning are trading 3 to 8 turns above non-AI software peers, per the Software Equity Group Q4 2025 report. Second, regulated-sector multiples have compressed because of CMS rate-setting rules and the FTC’s 2024 to 2025 challenges to PE roll-ups in healthcare; the result is a 2 to 4 turn discount on multi-site healthcare comps versus 2021 levels.
For the tax-structuring counterparts that often accompany these deals, the installment sale vs cash sale framework and the QSBS Section 1202 small business stock analysis are the working tax overlays. The founder shares guide covers the equity-structure side that determines what the founder actually nets at close.
TLDR and Key Takeaways
- Transaction comparables (also called precedent transactions, deal comps, or M&A comps) value a target by benchmarking against closed M&A deals in the same sector, capturing the all-in negotiated price including control premium and synergy share.
- The data comes from SEC EDGAR (free, audit-quality), S&P Capital IQ (~$13,000/seat/yr), Pitchbook (~$22,000/seat/yr), Refinitiv Deals Intelligence, and acquirer 10-K purchase price allocations under ASC 805.
- A defensible comp set is 8 to 15 deals over a 3 to 5 year window, screened for sector fit (NAICS plus qualitative), deal size band (under $50M, $50M to $250M, $250M to $1B, over $1B), and buyer type (strategic vs financial vs distressed).
- Enterprise value math is a five-line bridge: equity purchase price (fully diluted with treasury method on options under ASC 260) plus net debt plus preferred plus noncontrolling interest plus pension adjustment. Earnouts at fair value, not face value.
- Multiple choice depends on sector: EV / LTM EBITDA is the default, EV / NTM Revenue dominates software and biotech, P / TBV dominates financials, EV / Proved Reserves dominates upstream energy.
- Median control premium for U.S. public-target deals in 2024 was 32.4 percent (FactSet Mergerstat Review 2025). Strategic buyers pay 2 to 5 turn premiums over financial buyers; mega-deal mid-market mid-cap pricing follows a 4x to 16x EBITDA spread by size band.
- The output is a six-statistic distribution (min, 25th, median, mean, 75th, max) on each multiple. The negotiated range presented to the board is usually IQR (25th to 75th percentile).
- Footnotes explain dispersion: growth rate, margin profile, buyer type, cycle position, customer concentration. Without footnotes, the comp set is litigation-vulnerable under Item 1015 fairness opinion standards.
- Transaction comps fit in the football field alongside DCF, trading comps, and 52-week range. They are usually the highest of the four because they include control premium and synergy capture.
- Underweight transaction comps when the sample is thin (under 5 deals), stale (more than 24 months old in fast-moving sectors), regime-broken (pre Fed-hike cycle), or dominated by mega-deal outliers.
- The most-litigated mistakes: pulling EV from press releases instead of proxy footnotes, mixing pre- and post-IPO multiples, treating signed-but-not-closed deals as definitive, and failing to back out non-recurring items.
- 2026 sector medians range from 8.7x (specialty chemicals) to 14.5x (cybersecurity) with AI-native premiums of 3 to 8 turns and healthcare regulated-sector compression of 2 to 4 turns.